Life AI Net
首页
资讯库
计算器
目录
周刊
Hot
登录
简体中文
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
首页
资讯库
计算器
目录
周刊
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
登录
首页
资讯库
计算器
目录
More
滚动资讯
FierceBiotech
Pulnovo Medical scores $100M in finance round led by Medtronic
Lonza News
Lonza Group AG stock (CH0013841017): Why biopharma contract manufacturing now matters more for U.S. - AD HOC NEWS
10x Genomics Blog
Is Atera’s New Spatial Biology Platform Altering The Investment Case For 10x Genomics (TXG)? - simplywall.st
Brady Corporation
Milwaukee’s Brady Corp Buying Honeywell Division - Seehafer News
FierceBiotech
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech
Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
BioWorld
Pricing standoff leaves Australian patients in limbo
BioWorld
Mabwell turns to Hong Kong to fund ADC ambitions
BioWorld
Xuanzhu shares dip despite phase III ALK inhibitor data
FierceBiotech
Pulnovo Medical scores $100M in finance round led by Medtronic
Lonza News
Lonza Group AG stock (CH0013841017): Why biopharma contract manufacturing now matters more for U.S. - AD HOC NEWS
10x Genomics Blog
Is Atera’s New Spatial Biology Platform Altering The Investment Case For 10x Genomics (TXG)? - simplywall.st
Brady Corporation
Milwaukee’s Brady Corp Buying Honeywell Division - Seehafer News
FierceBiotech
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech
Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
BioWorld
Pricing standoff leaves Australian patients in limbo
BioWorld
Mabwell turns to Hong Kong to fund ADC ambitions
BioWorld
Xuanzhu shares dip despite phase III ALK inhibitor data
资讯库
FierceBiotech
2026年3月6日
Beam调整协议以保留碱基编辑技术,因合作伙伴解散
Beam调整协议以保留碱基编辑技术,因合作伙伴解散
原文
暂时没有全文,请查看原始来源。